Kansas: (913) 444-9696 | Missouri: (816) 777-2977

Dr. Michael

About Dr. Michael Catausan M.D.

Dr. Michael Catausan, MD, brings a wealth of experience to the medical field, with a career spanning diverse roles and leadership positions. He is board certified by the American Board of Family Medicine and holds a DEA Federal Narcotic License, demonstrating his commitment to excellence and compliance. Dr. Catausan serves as the Medical Director at Test Smartly Labs and has held that position since 2011.  His expertise extends across a spectrum, from emergency medicine to telemedicine, offering a distinctive perspective to the healthcare industry. Dr. Catausan earned his MD from the University of Missouri-Kansas City School of Medicine and furthered his academic journey by pursuing an MBA with a healthcare concentration at Southeast Missouri State University's Harrison College of Business and Computing. With a solid foundation in emergency medicine, leadership roles, and a commitment to patient care, Dr. Catausan continues to make significant contributions to the healthcare sector. He holds certification from the Wyoming Medical Board.

Hepatitis A Outbreak Linked to Frozen Clams: Should You Get Tested or Check Your Immunity?

A 2026 hepatitis A outbreak potentially linked to contaminated frozen clams raised concerns about exposure and immunity. If you've consumed affected shellfish, checking your hepatitis A vaccination status and understanding when testing is appropriate can help protect your health. Unvaccinated people with recent exposure may need preventive treatment within 14 days.

Could Your Supplements Contain Heavy Metals? Risks in Collagen & Seafood

Some collagen supplements and seafood products can contain trace amounts of heavy metals like mercury, lead, cadmium, or arsenic. While not every product poses a health risk, repeated exposure to elevated levels can affect your health over time. Knowing which products carry potential risks, how to check their quality, and when testing may be appropriate can help you make safer choices.

Hair Follicle Drug Testing for Employers: What the 2026 Workforce Drug Testing Data Reveals

The 2026 Quest Diagnostics report found that 19.1% of hair drug tests among workers in the general U.S. workforce were positive in 2025, highlighting patterns that shorter detection methods may miss. For employers, understanding these trends can help improve drug testing policies, identify potential workplace risks, and choose the right screening methods.

Go to Top